title: [Treatment options in non-Hodgkin lymphomas].
abstract: Histological diagnosis according to WHO classification and determination of usual prognostic factors are necessary to choose between treatment options in non-Hodgkin lymphomas. If an observation period could be frequently proposed to patients with indolent lymphoma, first line treatment usually includes the anti-CD20 monoclonal antibody rituximab (in type B lymphoma or CD20-expressing). A complete remission must be obtained in patients with aggressive lymphoma and the association of chemotherapy and rituximab, in B-cell subtype, is the standard therapeutic approach.
authors.affiliation: Service hématologie, Centre Henri-Becquerel, 76038 Rouen. herve.tilly@rouen.fnclcc.fr
authors.forename: Hervé
authors.initials: H
authors.lastname: Tilly
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D011241:Prednisone / Q000627:therapeutic use; D000069283:Rituximab; D033581:Stem Cell Transplantation; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone